Lifitegrast

Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease[1].

Product Specifications

CAS Number

[1025967-78-5]

Product Name Alternative

SAR 1118; SHP-606

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Integrin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Lifitegrast.html

Purity

99.29

Solubility

DMSO : ≥ 29 mg/mL

Smiles

O=C(O)[C@H](CC1=CC=CC(S(=O)(C)=O)=C1)NC(C2=C(Cl)C3=C(CN(C(C4=CC=C5C=COC5=C4)=O)CC3)C=C2Cl)=O

Molecular Formula

C29H24Cl2N2O7S

Molecular Weight

615.48

Precautions

H302, H312, H332

References & Citations

[1]Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14 (2) :207-15.|[2]Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118) . J Ocul Pharmacol Ther. 2013 May;29 (4) :395-402.|[3]Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) . Invest Ophthalmol Vis Sci. 2010 Oct;51 (10) :5198-204.